Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy

Ofelia A Alvarez, Hector Rodriguez-Cortes, Natasha Robinson, Noeline Lewis, Claudia Diaz Pow Sang, Gabriela Lopez-Mitnik, Carole Paley

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Adherence to long-term treatment is challenging. Deferasirox (DFX) is a daily oral iron chelator approved in the United States for transfusional iron overload. PROCEDURES: Twenty-one subjects with sickle cell disease (mean age 13.8±4.2y) received DFX 20 to 30 mg/kg daily for 1-year while on chronic blood transfusions. Good adherence to DFX was defined as ≥80% intake of prescribed dose. Adherence was assessed by monthly pill counts and calendars, and questionnaires at 1, 3, 6, and 12 months follow-up. RESULTS: Fifteen of 21 subjects (71%) were adherent to DFX according to self-reports, with 83% of the patients being adherent at 1 month, 89% at 3 months, 65% at 6 months, and 78% at 12 months. We were only able to document continuous good adherence in 43% of patients by pill counts because of poor bottle return. The discrepancy between pill counts and self-reports may be related to over-reporting, with the real adherence being lower. Parental involvement with DFX administration (P=0.03) and age ≤16 years (P=0.0055) correlated with adherence. We could not detect a significant correlation between serum ferritin declines and adherence. Conclusion: Seventy-one percent of patients adhered to DFX according to questionnaire responses but only 43% did according to pill counts. Adherence was poorer in adolescents older than 16 years of age and in patients who had no parental supervision of medications.

Original languageEnglish
Pages (from-to)739-744
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume31
Issue number10
DOIs
StatePublished - Oct 1 2009

Fingerprint

Sickle Cell Anemia
Self Report
Therapeutics
Iron Overload
Ferritins
Chelating Agents
Blood Transfusion
deferasirox
Iron
Serum

Keywords

  • Adherence
  • Children
  • Deferasirox
  • Sickle cell anemia
  • Sickle cell disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy. / Alvarez, Ofelia A; Rodriguez-Cortes, Hector; Robinson, Natasha; Lewis, Noeline; Pow Sang, Claudia Diaz; Lopez-Mitnik, Gabriela; Paley, Carole.

In: Journal of Pediatric Hematology/Oncology, Vol. 31, No. 10, 01.10.2009, p. 739-744.

Research output: Contribution to journalArticle

Alvarez, Ofelia A ; Rodriguez-Cortes, Hector ; Robinson, Natasha ; Lewis, Noeline ; Pow Sang, Claudia Diaz ; Lopez-Mitnik, Gabriela ; Paley, Carole. / Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy. In: Journal of Pediatric Hematology/Oncology. 2009 ; Vol. 31, No. 10. pp. 739-744.
@article{7cc0d38afd974f18bec490b9aa7f9a11,
title = "Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy",
abstract = "Background: Adherence to long-term treatment is challenging. Deferasirox (DFX) is a daily oral iron chelator approved in the United States for transfusional iron overload. PROCEDURES: Twenty-one subjects with sickle cell disease (mean age 13.8±4.2y) received DFX 20 to 30 mg/kg daily for 1-year while on chronic blood transfusions. Good adherence to DFX was defined as ≥80{\%} intake of prescribed dose. Adherence was assessed by monthly pill counts and calendars, and questionnaires at 1, 3, 6, and 12 months follow-up. RESULTS: Fifteen of 21 subjects (71{\%}) were adherent to DFX according to self-reports, with 83{\%} of the patients being adherent at 1 month, 89{\%} at 3 months, 65{\%} at 6 months, and 78{\%} at 12 months. We were only able to document continuous good adherence in 43{\%} of patients by pill counts because of poor bottle return. The discrepancy between pill counts and self-reports may be related to over-reporting, with the real adherence being lower. Parental involvement with DFX administration (P=0.03) and age ≤16 years (P=0.0055) correlated with adherence. We could not detect a significant correlation between serum ferritin declines and adherence. Conclusion: Seventy-one percent of patients adhered to DFX according to questionnaire responses but only 43{\%} did according to pill counts. Adherence was poorer in adolescents older than 16 years of age and in patients who had no parental supervision of medications.",
keywords = "Adherence, Children, Deferasirox, Sickle cell anemia, Sickle cell disease",
author = "Alvarez, {Ofelia A} and Hector Rodriguez-Cortes and Natasha Robinson and Noeline Lewis and {Pow Sang}, {Claudia Diaz} and Gabriela Lopez-Mitnik and Carole Paley",
year = "2009",
month = "10",
day = "1",
doi = "10.1097/MPH.0b013e3181b53363",
language = "English",
volume = "31",
pages = "739--744",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy

AU - Alvarez, Ofelia A

AU - Rodriguez-Cortes, Hector

AU - Robinson, Natasha

AU - Lewis, Noeline

AU - Pow Sang, Claudia Diaz

AU - Lopez-Mitnik, Gabriela

AU - Paley, Carole

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Background: Adherence to long-term treatment is challenging. Deferasirox (DFX) is a daily oral iron chelator approved in the United States for transfusional iron overload. PROCEDURES: Twenty-one subjects with sickle cell disease (mean age 13.8±4.2y) received DFX 20 to 30 mg/kg daily for 1-year while on chronic blood transfusions. Good adherence to DFX was defined as ≥80% intake of prescribed dose. Adherence was assessed by monthly pill counts and calendars, and questionnaires at 1, 3, 6, and 12 months follow-up. RESULTS: Fifteen of 21 subjects (71%) were adherent to DFX according to self-reports, with 83% of the patients being adherent at 1 month, 89% at 3 months, 65% at 6 months, and 78% at 12 months. We were only able to document continuous good adherence in 43% of patients by pill counts because of poor bottle return. The discrepancy between pill counts and self-reports may be related to over-reporting, with the real adherence being lower. Parental involvement with DFX administration (P=0.03) and age ≤16 years (P=0.0055) correlated with adherence. We could not detect a significant correlation between serum ferritin declines and adherence. Conclusion: Seventy-one percent of patients adhered to DFX according to questionnaire responses but only 43% did according to pill counts. Adherence was poorer in adolescents older than 16 years of age and in patients who had no parental supervision of medications.

AB - Background: Adherence to long-term treatment is challenging. Deferasirox (DFX) is a daily oral iron chelator approved in the United States for transfusional iron overload. PROCEDURES: Twenty-one subjects with sickle cell disease (mean age 13.8±4.2y) received DFX 20 to 30 mg/kg daily for 1-year while on chronic blood transfusions. Good adherence to DFX was defined as ≥80% intake of prescribed dose. Adherence was assessed by monthly pill counts and calendars, and questionnaires at 1, 3, 6, and 12 months follow-up. RESULTS: Fifteen of 21 subjects (71%) were adherent to DFX according to self-reports, with 83% of the patients being adherent at 1 month, 89% at 3 months, 65% at 6 months, and 78% at 12 months. We were only able to document continuous good adherence in 43% of patients by pill counts because of poor bottle return. The discrepancy between pill counts and self-reports may be related to over-reporting, with the real adherence being lower. Parental involvement with DFX administration (P=0.03) and age ≤16 years (P=0.0055) correlated with adherence. We could not detect a significant correlation between serum ferritin declines and adherence. Conclusion: Seventy-one percent of patients adhered to DFX according to questionnaire responses but only 43% did according to pill counts. Adherence was poorer in adolescents older than 16 years of age and in patients who had no parental supervision of medications.

KW - Adherence

KW - Children

KW - Deferasirox

KW - Sickle cell anemia

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=70349843630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349843630&partnerID=8YFLogxK

U2 - 10.1097/MPH.0b013e3181b53363

DO - 10.1097/MPH.0b013e3181b53363

M3 - Article

C2 - 19734806

AN - SCOPUS:70349843630

VL - 31

SP - 739

EP - 744

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 10

ER -